The institute also conducts public health awareness campaigns on common, underdiagnosed, undertreated diseases within its purview.

The three components—the Data, Biosample, and Genetic Repositories—accept submissions of database archives, biological specimens, and blood and DNA samples, respectively, and are responsible for proper storage, maintenance, and distribution of requested materials to qualified researchers.

[9] Source:[2] December 11, 1947—The Experimental Biology and Medicine Institute was established under Section 202 of Public Law (P.L.)

93—640) was signed into law to further research, education, and training in the field of connective tissue diseases.

The act authorized the creation of a national commission, centers for research and training in arthritis and rheumatic diseases, a data bank, and an overall plan to investigate the epidemiology, etiology, control, and prevention of these disorders.

2264 and Senate report with S. 1061, FY 1998 appropriations bills for Labor/HHS/Education, urged NIH and NIDDK to establish a diabetes research working group to develop a comprehensive plan for NIH-funded diabetes research that would recommend future initiatives and directions.

105–34), established a Special Statutory Funding Program for Type 1 Diabetes Research (now Section 330B of the Public Health Service Act).

The NIDDK, through authority granted by the HHS Secretary, has a leadership role in planning, administering, and evaluating the allocation of these funds.

106–310) entitled "Reducing the Burden of Diabetes Among Children and Youth" specified that the NIH conduct long-term epidemiology studies, support regional clinical research centers, and provide a national prevention effort relative to type 1 diabetes.

December 17, 2002—The Public Health Service Act amendment relating to diabetes research (P.L.

107–360) extended and augmented the Special Statutory Funding Program for Type 1 Diabetes Research.

December 8, 2003—Title VII, Subtitle D, Section 733 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (P.L.

108–173) authorized the NIDDK to conduct a pancreatic islet transplantation clinical trial that includes Medicare beneficiaries.

A provision of this law specified that the annual reports prepared by the NIDDK-led Diabetes Mellitus Interagency Coordinating Committee include an assessment of the federal activities and programs related to pancreatic islet transplantation.

September 2004—The reports accompanying the FY 2005 Senate and House Labor, HHS, and Education appropriations bills (Senate Report 108-345 and House Report108-636) called on the NIH and HHS to establish a national commission on digestive diseases to develop a long-range research plan.

The NIH director subsequently established the National Commission on Digestive Diseases under NIDDK leadership in August 2005.

February 17, 2009—President Barack Obama signed the American Recovery and Reinvestment Act (ARRA) of 2009 (P.L.

The NIDDK developed a plan to use its portion of the ARRA funds to meet the stimulus goals set forth in the Recovery Act.